Hongwei Y Yin

20130273063, Oct 17, 2013

Apr 19, 2011

13/642430

Haiyong Han - Chandler AZ, US
Daniel Von Hoff - Scottsdale AZ, US
Caroline Huynh Diep - Minneapolis MN, US
Hongwei Yin - Scottsdale AZ, US

THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ

C12Q 1/68

4241581, 435 611, 435 619, 435 32, 506 9, 514 75

Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of said subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.

20200338157, Oct 29, 2020

Jul 6, 2020

16/921610

- Phoenix AZ, US
- Flagstaff AZ, US
Hongwei "Holly" Yin - Phoenix AZ, US
Michael Valentine - Flagstaff AZ, US
Donald Chow - Phoenix AZ, US
Jolene Bowers - Flagstaff AZ, US
Paul Keim - Flagstaff AZ, US
Bridget Barker - Flagstaff AZ, US

A61K 38/13
A61K 31/7135
A61K 31/58
A61K 31/5377
A61K 31/5415
A61K 31/4196
A61K 31/496
A61K 31/495
A61K 45/06
A61K 31/138
A61K 31/277
A61K 31/353
A61K 31/404
A61K 31/4174
A61K 31/428
A61K 31/4741
A61K 31/609

The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may b

20200032351, Jan 30, 2020

Oct 3, 2019

16/592753

- Phoenix AZ, US
- Vancouver, CA
Jeffrey M. TRENT - Phoenix AZ, US
Anthony N. KARNEZIS - Vancouver, CA
David HUNTSMAN - Vancouver, CA
Hongwei "Holly" YIN - Phoenix AZ, US
Yemin WANG - Vancouver, CA

C12Q 1/6886
A61K 38/43
A61K 45/06
A61K 31/713
A61K 31/5025
C12N 15/113

The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The invention also relates to a method of treating a mammalian subject having SCCOHT or a predisposition for SCCOHT.

20190151405, May 23, 2019

Jan 17, 2019

16/250612

- Phoenix AZ, US
- Flagstaff AZ, US
Hongwei "Holly" Yin - Phoenix AZ, US
Michael Valentine - Flagstaff AZ, US
Donald Chow - Phoenix AZ, US
Jolene Bowers - Flagstaff AZ, US
Paul Keim - Flagstaff AZ, US
Bridget Barker - Flagstaff AZ, US

A61K 38/13
A61K 31/495
A61K 45/06
A61K 31/4196
A61K 31/7135
A61K 31/5415
A61K 31/5377
A61K 31/58
A61K 31/609
A61K 31/4741
A61K 31/428
A61K 31/4174
A61K 31/404
A61K 31/353
A61K 31/277
A61K 31/138
A61K 31/496

The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may b

20170107578, Apr 20, 2017

Mar 23, 2015

15/127965

- Phoenix AZ, US
- Vancouver, CA
David Craig - Phoenix AZ, US
Jeffrey M. Trent - Phoenix AZ, US
Anthony N. Karnezis - Vancouver, CA
David Huntsman - Vancouver, CA
Hongwei Yin - Phoenix AZ, US
Yemin Wang - Vancouver, CA

C12Q 1/68
A61K 31/5025
C12N 15/113

The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The invention also relates to a method of treating a mammalian subject having SCCOHT or a predisposition for SCCOHT.

20160346285, Dec 1, 2016

Jun 20, 2016

15/186636

- Phoenix AZ, US
Daniel VON HOFF - Scottsdale AZ, US
Caroline H. DIEP - Minneapolis MN, US
Hongwei YIN - Scottsdale AZ, US

THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ

A61K 31/519
C12Q 1/68
A61K 9/00

Methods of tests that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer that are likely or unlikely to respond to treatment with BTK inhibitors; methods of treating subjects based on identification of the subjects as likely to respond to treatment with BTK inhibitors; therapeutic targets for cancers, particularly cancers with inactivated DPC4 gene or protein; methods of screening of new therapeutic agents using the target; pharmaceutical composition comprising BTK inhibitors, such as PCI-32765 or derivatives thereof, for cancer treatment; and kits that facilitate the performance of the methods are disclosed.

20160143987, May 26, 2016

Nov 24, 2015

14/949965

- Phoenix AZ, US
- Flagstaff AZ, US
Hongwei "Holly" Yin - Phoenix AZ, US
Michael Valentine - Flagstaff AZ, US
Donald Chow - Phoenix AZ, US
Jolene Bowers - Flagstaff AZ, US
Paul Keim - Flagstaff AZ, US

A61K 38/13
A61K 31/58
A61K 31/4196
A61K 31/5377
A61K 31/5415
A61K 31/7135
A61K 33/24

The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may be Valley Fever.

20160146784, May 26, 2016

Jul 9, 2014

14/904363

- Phoenix AZ, US
Harshil Dhruv - Phoenix AZ, US
Hongwei Yin - Phoenix AZ, US

G01N 33/50
A61K 31/53
A61K 31/47
A61K 31/635
A61K 31/542
A61K 31/433
A61K 31/498
A61K 31/437
A61K 31/4045
A61K 31/4155
A61K 31/5513
A61K 31/426
A61K 31/55
A61K 31/519
A61K 31/422
A61K 31/4192
A61K 31/541
A61K 31/167

The present disclosure is directed to methods of screening a compound for modulating activity at a TNF-like weak inducer of apoptosis (TWEAK) binding site on a cysteine-rich domain (CRD) of fibroblast growth factor-inducible 14 (Fn14). The present disclosure also provides heterocyclic compounds and pharmaceutically acceptable salts thereof and methods for the prevention, treatment, and amelioration of cell proliferative disorders with these compounds.